TG Therapeutics price target raised to $23 from $19 at Jefferies

Jefferies analyst Chris Howerton raised the firm’s price target on TG Therapeutics to $23 from $19 and keeps a Buy rating on the shares after the FDA approved Briumvi for the treatment of relapsing forms of multiple sclerosis. Briumvi’s one-hour infusion times and twice-yearly administration will be "a main selling point to patients," while its "low price will be attractive to payers," said Howerton, who models about $2B in peak U.S. RMS sales.